Online citations, reference lists, and bibliographies.
← Back to Search

Serial Measurements Of Mesothelioma Serum Biomarkers In Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study

K. Hollevoet, J. Van Cleemput, Joël Thimpont, P. de Vuyst, L. Bosquée, K. Nackaerts, P. Germonpré, S. Vansteelandt, Y. Kishi, J. Delanghe, J. Van Meerbeeck
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction:Soluble mesothelin (SM) and megakaryocyte potentiating factor (MPF) are serum biomarkers of mesothelioma. This study aims to examine the longitudinal behavior of SM and MPF in controls to gain insight in the optimal use of these biomarkers in screening. Methods:Asbestos-exposed individuals, with no malignant disease at inclusion, were surveilled for 2 years with annual measurements of SM and MPF. Fixed thresholds were set at 2.10 nmol/L for SM and 13.10 ng/ml for MPF. Longitudinal biomarker analysis, using a random intercept model, estimated the association with age and glomerular filtration rate (GFR), and the intraclass correlation. The latter represents the proportion of total biomarker variance accounted for by the between-individual variance. Results:A total of 215 participants were included, of whom 179 and 137 provided a second sample and third sample, respectively. Two participants with normal SM and MPF levels presented afterward with mesothelioma and lung cancer, respectively. Participants with elevated biomarker levels were typically older and had a lower GFR. During follow-up, biomarker levels significantly increased. Longitudinal analysis indicated that this was in part due to aging, while changes in GFR had a less pronounced effect on serial biomarker measurements. SM and MPF had a high intraclass correlation of 0.81 and 0.78, respectively, which implies that a single biomarker measurement and fixed threshold are suboptimal in screening. Conclusions:The longitudinal behavior of SM and MPF in controls indicates that a biomarker-based screening approach can benefit from the incorporation of serial measurements and individual-specific screening rules, adjusted for age and GFR. Large-scale validation remains nevertheless mandatory to elucidate whether such an approach can improve the early detection of mesothelioma.
This paper references
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.7326/0003-4819-150-9-200905050-00006
A new equation to estimate glomerular filtration rate.
A. Levey (2009)
10.1373/clinchem.2008.121913
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.
K. Hollevoet (2009)
10.1016/S0046-8177(03)00177-1
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas.
H. Frierson (2003)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1164/rccm.200806-955ED
Screening for mesothelioma: more harm than good?
J. Van Meerbeeck (2008)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1053/j.semtcvs.2009.06.007
Current status of screening for malignant pleural mesothelioma.
H. Pass (2009)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers
S. Skates (1995)
10.1007/s00204-010-0580-2
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos
M. Gube (2010)
Glomerular filtration rate is a confounder for determination of serum soluble mesothelin
Kevin Hollevoet (2009)
10.1093/JNCI/93.14.1054
Phases of biomarker development for early detection of cancer.
M. Pepe (2001)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1016/j.lungcan.2007.12.025
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
O. Røe (2008)
10.1016/j.lungcan.2008.02.012
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
K. Iwahori (2008)
10.1016/j.mrgentox.2008.06.011
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
M. Amati (2008)
Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
C. Crump (2000)
10.1016/J.HOC.2005.09.007
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
10.1158/1078-0432.CCR-03-0801
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.4137/BMI.S3927
Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum
D. Weber (2010)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
BK-Report 1/2007 Faserjahre
M Arendt (2007)



This paper is referenced by
10.1155/2013/874212
Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
J. Creaney (2013)
10.1158/1055-9965.EPI-11-0993
Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma
N. Rizk (2012)
10.1111/j.1440-1843.2011.02020.x
Facts, rumours and speculations about the mesothelioma epidemic
J. Van Meerbeeck (2011)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1007/s00420-013-0853-1
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers
M. K. Felten (2013)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
10.1016/j.cllc.2011.12.004
Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption.
K. Hollevoet (2012)
10.1186/s12885-017-3375-5
Calretinin as a blood-based biomarker for mesothelioma
G. Johnen (2017)
10.1038/s41598-018-32315-3
Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers
G. Johnen (2018)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.3389/fonc.2019.00740
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
I. Cavallari (2019)
10.1007/s12199-015-0477-z
Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population
M. Yu (2015)
10.5772/53397
Recent Advances in Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma
C. Asteriou (2013)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1016/j.shaw.2020.07.009
Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders
E. Park (2020)
10.1016/b978-0-12-394384-2.00006-1
Asbestos-Related Disease
J. R. Portal (2012)
10.1145/2506583.2512358
Biomarkers in Immunology: from Concepts to Applications
P. Zhang (2013)
10.2478/raon-2020-0011
Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
K. Goričar (2020)
10.1007/978-1-4471-2825-0_19
Malignant Mesothelioma: Molecular Markers
E. Kettunen (2014)
10.1007/s12032-012-0422-6
Individual predictors of increased serum mesothelin in asbestos-exposed workers
R. Filiberti (2013)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.1159/000355687
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
10.1007/978-3-030-16884-1_3
Screening Issues in Exposed Subjects and Early Diagnosis
M. Mencoboni (2019)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
Semantic Scholar Logo Some data provided by SemanticScholar